FluoroPharma Medical, a developer of imaging agents for use with positron emission tomography (PET) scanning, helps to make visible subtle biological processes occurring deep within the body. From its founding in 2003, with technology licensed from Massachusetts General Hospital, the company has been steadily developing important imaging drugs for diagnostic testing, including much needed PET tracers for use in the diagnosis of cardiac disease at the cellular and molecular level. Below are some of the key facts relating to FluoroPharma.
• Current methods do not assess myocardial health • Higher diagnostic accuracy • Alternative to invasive procedures
• Proprietary products that support new technologies for personalized medicine • Two Phase II ready products with short study timelines, both directed to very large markets • Robust pipeline of first-in-class imaging products • Technology compatible with current clinical practice, with reliable reimbursement in place • Clear and focused plan of value creation • Experienced management and world-class advisors • Intellectual property in place to protect proprietary innovations around the world
• Global market for imaging agents expected to exceed $15 billion by 2015 • Increasing demand for personalized medicine • Growing volume of diagnostic exams and associated equipment sales • Aging population expanding commercialization potential • Global spread of new technologies, with Asia-Pacific and other high growth markets • Drive for cost effective analysis to avoid unnecessary or inappropriate operations
For more information, see the company website at www.FluoroPharma.com